Latest News and Press Releases

Lugano, Switzerland – April 2, 2025 – Helsinn Group (“Helsinn”), a global pharmaceutical company with a track record of nearly fifty years of commercial execution and a strong focus in supportive...

Farma Mondo Group and Helsinn sign exclusive partnership to commercialize AKYNZEO® in the Baltic region CHIASSO, Switzerland and LUGANO, Switzerland – November 28, 2022 – Farma Mondo Group, a...

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...

Helsinn announces launch of oral formulation of Akynzeo® in China Lugano, Switzerland, June 9, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare disease...

Helsinn Group announces FDA approval of a new liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) injection in the United States Lugano, Switzerland, June 2, 2020 – Helsinn, a Swiss...

Helsinn announces European approval of the IV formulation of AKYNZEO® (fosnetupitant / palonosetron) Lugano, Switzerland, March 23, 2020 – Helsinn, the Swiss pharmaceutical group focused on building...

Lugano, Switzerland, December 13, 2019 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, is presenting a scientific poster assessing acute care involving...

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code,  J1454, in the US, by the...

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code,  J1454, in the US, by the...

Helsinn and CJ Healthcare announce the approval of AKYNZEO® oral formulation in Korea CINV is one of the most common and distressing side effects of cancer chemotherapyIncluded as a treatment option...